H.C. Wainwright has reaffirmed its Buy rating on CRISPR Therapeutics (NASDAQ: CRSP) with a price target of $80, implying roughly 34% upside from the stock’s latest close of $57.72. The reiteration follows updated clinical data for the company’s experimental therapy CTX310, which targets lipid disorders.
The analyst cited updated 12-month follow-up results from 15 patients in the Phase 1a trial of CTX310, presented at the European Society of Cardiology. The 0.8 mg/kg cohort demonstrated sustained reductions in key lipid markers, including a 78.6% decrease in ANGPTL3, up from 73% at Day 30 and consistent with prior 12-month data. Low-density lipoprotein cholesterol (LDL-C) fell by 52.5%, deepening from 48.9% at Day 60, while triglycerides declined by 47.8%, remaining nearly 50% below baseline levels. Additional reductions were observed in apolipoprotein B (37.2%), non-HDL cholesterol (52.0%), and triglyceride-rich lipoprotein cholesterol (71.7%).
Phase 1b testing is underway using a flat dosing regimen designed to achieve exposure equivalent to the 0.8 mg/kg cohort in Phase 1a. H.C. Wainwright maintained its 25% probability of approval for CTX310, with no changes to valuation estimates. The next catalyst for CTX310 is expected in the second half of 2026, when an update on the Phase 1b sHTG cohort is anticipated.
CRISPR Therapeutics also highlighted a recent regulatory development for its approved gene therapy CASGEVY. The U.S. Food and Drug Administration expanded the label to include patients aged two years and older with sickle cell disease and transfusion-dependent beta-thalassemia. Analysts at Citizens estimated this expansion could expand the total addressable market for CASGEVY by 10–15%. Citizens separately reiterated a Market Outperform rating and a $80 price target for CRISPR Therapeutics.
CRISPR Therapeutics’ market capitalization stands at approximately $5.58 billion, with shares trading at $57.72 at the time of the rating reiteration.
